{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "When a California judge handed down a $12.5 million false-advertising judgment against the maker of an ephedra-based weight-loss pill late last month, he also issued what amounted to a bill of reproach against the science of dietary supplements. The company, Cytodyne Technologies, maker of Xenadrine RFA-1, the supplement implicated in the death of a Baltimore Orioles pitcher, had not just exaggerated the findings of clinical trials it commissioned, Superior Court Judge Ronald L. Styn said in ruling on a class-action suit, but had also cajoled some researchers into fudging results in published scientific articles.", "headline": {"main": "Studies of Dietary Supplements Come Under Growing Scrutiny"}, "abstract": "Swelling tide of litigation raises serious questions about way makers of dietary supplements use--and often misuse--promise of scientific proof to market their products; in last eight months, three leading manufacturers of weight-loss pills have been hit with false-advertising verdicts in millions of dollars; fourth has been rebuked by federal judge for hiding evidence; Missouri attorney general and group of district attorneys in California have brought false-advertising suits against manufacturers; Congress is demanding research records of Cytodyne, maker of ephedra-based weight-loss pill Xenadrine RFA-1, supplement implicated in death of Baltimore Orioles pitcher; Judge Ronald L Styn, who handed down $12.5 million false-advertising judgment against Cytodyne, says researchers set out to create study that 'justified money being spent' by Cytodyne and would ensure that they received further work from company; Cytodyne and several other manufacturers have refashioned weight-loss products without ephedra, but experts say switch in ingredients does nothing to alter industry's reliance on questionable science; supplement makers are not obliged to do any research, but have embraced it as good advertising tool; experts contend that because industry is not regulated, its research is sometimes less than strictly scientific; photos (M)", "print_page": "1", "word_count": 2431, "_id": "4fd274088eb7c8105d831aac", "snippet": "When a California judge handed down a $12.5 million false-advertising judgment against the maker of an ephedra-based weight-loss pill late last month, he also issued what amounted to a bill of reproach against the science of dietary supplements.    ...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/06/23/us/studies-of-dietary-supplements-come-under-growing-scrutiny.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "STYN, RONALD L"}, {"name": "glocations", "value": "MISSOURI"}, {"name": "glocations", "value": "CALIFORNIA"}, {"name": "organizations", "value": "CYTODYNE TECHNOLOGIES"}, {"name": "subject", "value": "EPHEDRA (HERB)"}, {"name": "subject", "value": "FRAUDS AND SWINDLING"}, {"name": "subject", "value": "MISLEADING AND DECEPTIVE ADVERTISING"}, {"name": "subject", "value": "ADVERTISING"}, {"name": "subject", "value": "CONSUMER PROTECTION"}, {"name": "subject", "value": "XENADRINE (SUPPLEMENT)"}, {"name": "subject", "value": "REGULATION AND DEREGULATION OF INDUSTRY"}, {"name": "subject", "value": "WEIGHT"}, {"name": "subject", "value": "DIETARY SUPPLEMENTS AND HERBAL REMEDIES"}, {"name": "subject", "value": "ETHICS"}, {"name": "subject", "value": "SUITS AND LITIGATION"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "DECISIONS AND VERDICTS"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Ford", "lastname": "FESSENDEN"}], "original": "By FORD FESSENDEN"}, "document_type": "article", "pub_date": "2003-06-23T00:00:00Z", "section_name": "Front Page; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "Week in Review Desk", "lead_paragraph": "PATIENTS are beginning to treat depression with respect. Whether their doctors are ready to do so is less clear. A study in the current issue of The Journal of the American Medical Association finds that almost six in 10 Americans who suffer depression seek treatment in a given year. A decade ago, the figure was one in three.", "headline": {"main": "The Nation: Side Effects; Your Zoloft Might Prevent a Heart Attack"}, "abstract": "Peter D Kramer comment on research showing that depression triples or quadruples risk of cardiac death, with most acute danger in wake of first heart attacks; reports that antidepressants are linked to extraordinary reduction in death or heart attack recurrence, thirty or forty percent, but how they do so is yet unclear (M)", "print_page": "3", "word_count": 907, "_id": "4fd28f668eb7c8105d866e2b", "snippet": "PATIENTS are beginning to treat depression with respect. Whether their doctors are ready to do so is less clear.    A study in the current issue of The Journal of the American Medical Association finds that almost six in 10 Americans who suffer...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/06/22/weekinreview/the-nation-side-effects-your-zoloft-might-prevent-a-heart-attack.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "subject", "value": "HEART"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "MENTAL HEALTH AND DISORDERS"}, {"name": "subject", "value": "ANTIDEPRESSANTS"}, {"name": "subject", "value": "DEPRESSION (MENTAL)"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1}], "original": "By PETER D. KRAMER"}, "document_type": "article", "pub_date": "2003-06-22T00:00:00Z", "section_name": "Health; Week in Review"}, {"type_of_material": "News", "blog": [], "news_desk": "Week in Review Desk", "lead_paragraph": "HAIL America, land of the speedy and home of the shaved, where the list of short things we love keeps getting longer. We love brief wars and abbreviated weapons, instant messaging and prescient gratification. A duchess said you can't be too trim; editors say the same about stories. But the one thing we don't like short and never have is our men. There is a harsh rule of thumb about male height, and it measures six feet and counting. As study after study has shown, tall men give nearly all the orders, win most elections, monopolize girls and monopolies, and disproportionately splay their elongated limbs across the cushy unconfines of first-class cabins. By the simple act of striding into a room, taller than average men are accorded a host of positive attributes having little or nothing to do with height: a high IQ, talent, competence, trustworthiness, even kindness.", "headline": {"main": "Ideas & Trends; Short Men, Short Shrift. Are Drugs The Answer?"}, "abstract": "Natalie Angier comment on American society that strongly favors taller men, in light of panel recommendation that FDA approve use of genetically engineered human growth hormone for healthy children who are 'idiopathically' short, meaning they are at bottom of growth curves without having hormone deficiency; photos; graph (M)", "print_page": "12", "word_count": 1174, "_id": "4fd274138eb7c8105d8320d2", "snippet": "HAIL America, land of the speedy and home of the shaved, where the list of short things we love keeps getting longer. We love brief wars and abbreviated weapons, instant messaging and prescient gratification. A duchess said you can't be too trim;...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/06/22/weekinreview/ideas-trends-short-men-short-shrift-are-drugs-the-answer.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "subject", "value": "HEIGHT (STATURE)"}, {"name": "subject", "value": "HORMONES"}, {"name": "subject", "value": "MEN"}, {"name": "subject", "value": "CHILDREN AND YOUTH"}, {"name": "subject", "value": "HUMAN GROWTH HORMONE"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Natalie", "lastname": "ANGIER"}], "original": "By NATALIE ANGIER"}, "document_type": "article", "pub_date": "2003-06-22T00:00:00Z", "section_name": "Week in Review"}], "meta": {"hits": 3, "offset": 0, "time": 41}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}